Clinical observations of sertindole in 53 hospitalised patients with psychotic disorders

Clinical Drug Investigation

Volumn 25, Issue 1, 2005, Pages 79-83

  Steinert, Tilman ^a,b   Hauger, Barbara ^a   Eckardt, Jürgen ^a   Schmid, Peter ^a  

^a UNIVERSITY OF ULM   (Germany)

^b Psychiatrical Center Weissenau   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR; ANTIDEPRESSANT AGENT; ANTIPARKINSON AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; BIPERIDEN; BUTYROPHENONE DERIVATIVE; CLOZAPINE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; FLUPENTIXOL; HALOPERIDOL; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; RISPERIDONE; SEROTONIN 2 RECEPTOR; SERTINDOLE; TRICYCLIC ANTIDEPRESSANT AGENT; ZOTEPINE;

ADULT; AGED; AKATHISIA; ARTICLE; CLINICAL TRIAL; CONSTIPATION; DIZZINESS; DROWSINESS; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG MARKETING; DRUG MECHANISM; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; DYSKINESIA; DYSPNEA; DYSTONIA; EJACULATION DISORDER; EXTRAPYRAMIDAL SYMPTOM; FEMALE; FUNCTIONAL ASSESSMENT; HEART ARRHYTHMIA; HUMAN; HYPERKINESIA; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; MONOTHERAPY; NOSE CONGESTION; ORTHOSTATIC HYPOTENSION; PARESTHESIA; PARKINSONISM; PERIPHERAL EDEMA; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOSIS; QT PROLONGATION; RISK BENEFIT ANALYSIS; SCHIZOPHRENIA; SIDE EFFECT; SLEEP DISORDER; SYMPTOM; THIRST; TREATMENT FAILURE; WEIGHT GAIN; XEROSTOMIA;

EID: 19644387320     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200525010-00007     Document Type: Article

References (20)

1. Bickmann E, Große K, Laux G. Klinische Beobachtungen an schizophrenen Patienten unter Behandlung mit Sertindol. Psychopharmakotherapie 2001; 8: 28-34
2. Hyttel J, Arnt J, Costall B, et al. Pharmacological profile of the atypical neuroleptic sertindole. Clin Neuropharmacol 1992; 15 Suppl. 1: 267A-8
3. 1 receptors (ex vivo radio receptor binding studies). J Neural Transm Gen Sect 1992; 89: 61-9
4. Sanchez C, Arnt J, Costall B, et al. Sertindole: a limbic-selective neuroleptic with potent anxiolytic effects. Drug Dev Res 1995; 34: 19-29
5. Domeney AM, Arnt J, Costall B, et al. Effect of sertindole on raised mesolimbic dopaminergic activity in the rat. Drug Dev Res 1994; 31: 175-85
6. Daniel DG, Wozniak P, Mack RJ, et al. Long term efficacy and safety comparison of sertindole and haloperidol in the treatment of schizophrenia. Psychopharmacol Bull 1998; 34: 61-9
7. Lee AM, Knoll JL, Suppes T. The atypical antipsychotic sertindole: a case series. J Clin Psychiatry 1997; 58: 410-6
8. Brown LA, Levin GM. Sertindole, a new atypical antipsychotic for the treatment of schizophrenia. Pharmacotherapy 1998; 18: 69-83
9. Fritze J, Bandelow B. QT-Verlängerung und das neue, atypische Neuroleptikum Sertindol. Psychopharmakotherapie 1998; 5: 115-20
10. Lundbeck A/S, Sertindole: Product Monograph. Copenhagen: H. Lundbeck A/S, 1997: 6-81
11. Lundbeck A/S. Sertindole: summary of product characteristics. Copenhagen: H. Lundbeck A/S, 1996: 3-13
12. Tamminga CA, Mack RJ, Granneman GR, et al. Sertindole in the treatment of psychosis in schizophrenia: efficacy and safety. Int Clin Psychopharmacol 1997; 12 Suppl. 1: 29-35
13. Van Kammen DP, McEvoy JP, Targum SD, et al. A randomised, controlled, dose-ranging trial of sertindole in patients with schizophrenia. Psychopharmacology 1996; 124: 168-75
14. Zimbroff DL, Kane JM, Tamminga CA, et al. A controlled, dose-response study of sertindole and haloperidol in schizophrenia. Am J Psychiatry 1997; 154: 782-91
15. Editorial. Zum Risikoprofil von Sertindol (Serdolect). Arzneitelegramm 1997; 12: 128
16. American Psychiatric Association (APA). DSM-III-R. Diagnostic and statistical manual of mental disorders. 3rd rev. ed. Washington: APA, 1987
17. CIPS. Internationale Skalen für Psychiatrie. Weinheim: Beliz, 1986
18. International statistical classification of diseases and related health problems, tenth revision. Geneva: World Health Organization, 1992
19. Hale A, Azorin JM, Kasper S, et al. Sertindole improves both the positive and negative symptoms of schizophrenia: results of a phase III trial. Int J Psychiat Clin Pract 2000; 4 (1): 55-62
20. Azorin JM, Toumi M, Sloth-Nielsen M. Sertindole is well tolerated and demonstrates efficacy advantages over risperidone in the treatment of moderate to severe schizophrenia [abstract]. Eur Neuropsychopharmacol 2002; 12 Suppl. 3: S300